WASHINGTON, D.C. September 10, 2020

Chairman Takano, Ranking Member Roe, and members of the committee, thank you for the opportunity to provide our views on these important pieces of legislation.

ZERO - The End of Prostate Cancer and the three million American men - including 500,000 veterans - living with prostate cancer along with their families strongly support H.R. 6092, the Veterans Prostate Cancer Research and Treatment Act, which would establish a national clinical pathway for prostate cancer treatment and a national prostate cancer registry among veterans.

Clinical pathways are critical for establishing better health outcomes for veterans and are based on multidisciplinary research. A prostate cancer clinical pathway would cover a patient’s prostate cancer journey from early detection to advanced disease and end-of-life care.

Further, H.R. 6092 would require the VA to create a national prostate cancer care implementation program, which would coordinate and standardize prostate cancer care and treatment efforts across all VA entities, evaluate prostate cancer care quality and cost, and establish a national education plan aimed at VA administrators, providers, and patients.

Prostate cancer is the most common solid tumor cancer treated within the VA. It is long overdue that we protect our nation’s protectors, who fought to defend our nation, against the ravages of prostate cancer. This bill strengthens early detection and standardized care to help ensure that veterans have a 99 percent survival rate by giving them a fighting chance in their personal battles against prostate cancer.

Thank you.

Sincerely,

Jamie Bearse
CEO & President
ZERO – The End of Prostate Cancer